Suchen
Connect Biopharma Holdings Ltd
CNTBZur Watchlist hinzufügen
2.380USD
-0.100-4.03%
Handelsschluss 05/15, 16:00（ET）Kurse um 15 Minuten verzögert
149.85MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Connect Biopharma Holdings Ltd Unternehmen
Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4Rα, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
Connect Biopharma Holdings Ltd Informationen
BörsenkürzelCNTB
Name des UnternehmensConnect Biopharma Holdings Ltd
IPO-datumMar 19, 2021
CEOQuart (Barry D)
Anzahl der mitarbeiter62
WertpapierartOrdinary Share
GeschäftsjahresendeMar 19
Addresse3580 Carmel Mountain Road, Suite 200
StadtSAN DIEGO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl92130
Telefon18587271040
Websitehttps://www.connectbiopharm.com
BörsenkürzelCNTB
IPO-datumMar 19, 2021
CEOQuart (Barry D)
Führungskräfte von Connect Biopharma Holdings Ltd
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
82.82K
+3.40%
Ms. Lisa Peraza
Ms. Lisa Peraza
Vice President - Finance
Vice President - Finance
45.19K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
10.00K
--
Dr. Jean I. Liu, J.D.
Dr. Jean I. Liu, J.D.
Independent Director
Independent Director
5.06K
--
Dr. Kan Chen, Ph.D.
Dr. Kan Chen, Ph.D.
Independent Director
Independent Director
--
--
Mr. David L. Szekeres
Mr. David L. Szekeres
President
President
--
--
Mr. James Z. Huang
Mr. James Z. Huang
Independent Director
Independent Director
--
--
Mr. James A. (Jim) Schoeneck
Mr. James A. (Jim) Schoeneck
Director
Director
--
--
Kimberly Kimberly
Kimberly Kimberly
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Barry D. Quart, Pharm.D.
Dr. Barry D. Quart, Pharm.D.
Chief Executive Officer and Director
Chief Executive Officer and Director
224.03K
+41.13%
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Dr. Kleanthis G. Xanthopoulos, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
82.82K
+3.40%
Ms. Lisa Peraza
Ms. Lisa Peraza
Vice President - Finance
Vice President - Finance
45.19K
--
Ms. Karen J. Wilson, CPA
Ms. Karen J. Wilson, CPA
Independent Director
Independent Director
10.00K
--
Dr. Jean I. Liu, J.D.
Dr. Jean I. Liu, J.D.
Independent Director
Independent Director
5.06K
--
Dr. Kan Chen, Ph.D.
Dr. Kan Chen, Ph.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Thu, May 14
Aktualisiert: Thu, May 14
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Panacea Venture
20.90%
BioFortune Inc
9.51%
Wei (Zheng)
7.97%
Qiming Venture Partners
7.69%
Shanghai Minhui Enterprise Management Consulting Partnership
7.61%
Andere
46.33%
Aktionäre
Aktionäre
Anteil
Panacea Venture
20.90%
BioFortune Inc
9.51%
Wei (Zheng)
7.97%
Qiming Venture Partners
7.69%
Shanghai Minhui Enterprise Management Consulting Partnership
7.61%
Andere
46.33%
Aktionärstypen
Aktionäre
Anteil
Venture Capital
37.85%
Corporation
27.49%
Individual Investor
9.98%
Hedge Fund
9.43%
Investment Advisor/Hedge Fund
2.46%
Investment Advisor
1.54%
Private Equity
1.40%
Research Firm
0.15%
Pension Fund
0.14%
Andere
9.56%
Institutionelle Beteiligung
Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
51
29.94M
52.97%
+8.11M
2025Q4
39
23.82M
44.06%
--
2025Q3
44
23.82M
51.87%
-292.56K
2025Q2
43
24.11M
49.99%
-302.92K
2025Q1
42
24.43M
50.72%
-3.65M
2024Q4
48
24.78M
51.96%
+236.30K
2024Q3
55
24.55M
53.49%
-34.12K
2024Q2
62
24.58M
57.85%
+441.50K
2024Q1
65
24.14M
48.89%
-2.80M
2023Q4
72
21.31M
33.82%
+215.31K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Panacea Venture
12.00M
21.47%
-1.95M
-13.98%
Nov 26, 2025
BioFortune Inc
5.99M
10.71%
-170.59K
-2.77%
Dec 31, 2025
Wei (Zheng)
5.02M
8.97%
-210.89K
-4.03%
Dec 31, 2025
Qiming Venture Partners
4.84M
8.66%
--
--
Mar 21, 2025
Shanghai Minhui Enterprise Management Consulting Partnership
5.31M
9.49%
--
--
Mar 21, 2025
Ikarian Capital LLC
4.79M
8.57%
+4.79M
--
Dec 31, 2025
Advantech Capital II L.P.
4.76M
8.52%
--
--
Mar 21, 2025
Lilly Asia Ventures
3.34M
5.97%
--
--
Mar 21, 2025
Boothbay Fund Management, LLC
1.23M
2.21%
+1.23M
--
Dec 31, 2025
Perceptive Advisors LLC
792.70K
1.42%
+792.70K
--
Dec 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
SPDR Portfolio Emerging Markets ETF
0%
SPDR Portfolio Emerging Markets ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
